Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib vs Adalimumab in Active Rheumatoid Arthritis (FILRA)
NCT06527534Phase 4Recruiting
- Sponsor
- Università degli Studi di Verona
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of filgotinib in rheumatoid arthritis (RA) (2 arms), sponsored by Università degli Studi di Verona. Primary endpoint: micro RNA expression at 12 weeks. Started Jul 2024; status: recruiting.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06527534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06527534.